Priority Health has received high ratings from the state of Michigan for its Michigan Medicaid health plans, indicating their “above average” performance.
Grand Rapids, Michigan — On the heels of having received 5-star ratings from CMS for several of its Medicare Advantage plans, Priority Health has received a 4-apple rating, indicating “above average” performance, from Michigan for its Michigan Medicaid health plans. These plans include Children’s Special Health Care Services and Healthy Michigan Plan, and they were compared with all Michigan Medicaid health plans
Priority Health’s plans were recognized for their performance in 5 areas: doctors’ communication and service, getting care, keeping kids healthy, living will illness, and taking care of women.
“This is a direct reflection of the hard work that our teams put in every day to ensure we are providing the best possible care for our most vulnerable populations,” noted Praveen Thadani, president, in a statement. “Whether it is through our unique maternal and infant health programs, or hands-on care from our community health workers, we are committed to helping our members live happy and healthy lives.”
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS
September 8th 2023Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.
Listen
What We’re Reading: New HPV Screenings; Lung Cancer Pills; Migraine Relief Device
November 9th 2023A study suggests that human papillomavirus (HPV) screenings should be updated due to effective HPV vaccines; a new study shows that osimertinib (Tagrisso, AstraZeneca) reduced both the 5-year risk of recurrent cancer and the risk of death in patients with stage 1B to 3A lung cancer; a new smartphone-controlled technology could help those who suffer from migraines.
Read More